File(s) not publicly available
Preventive treatments to slow substantia nigra damage and Parkinson's disease progression: A critical perspective review
journal contributionposted on 2022-09-28, 09:29 authored by G Bjørklund, M Dadar, G Anderson, S Chirumbolo, Michael Maes
Restoring the lost physiological functions of the substantia nigra in Parkinson's disease (PD) is an important goal of PD therapy. The present article reviews a) novel drug targets that should be targeted to slow PD progression, and b) clinical and experimental research data reporting new treatments targeting immune-inflammatory and oxidative pathways. A systematic search was performed based on the major databases, i.e., ScienceDirect, Web of Science, PubMed, CABI Direct databases, and Scopus, on relevant studies performed from 1900 to 2020. This review considers the crucial roles of mitochondria and immune-inflammatory and oxidative pathways in the pathophysiology of PD. High levels of oxidative stress in the substantia nigra, as well as modifications in glutathione regulation, contribute to mitochondrial dysfunction, with a decline in complex I of the mitochondrial electron transport chain reported in PD patients. Many papers suggest that targeting antioxidative systems is a crucial aspect of preventive and protective therapies, even justifying the utilization of N-acetylcysteine (NAC) supplementation to fortify the protection afforded by intracellular glutathione. Dietary recommended panels including ketogenetic diet, muscular exercise, nutraceutical supplementation including NAC, glutathione, nicotine, caffeine, melatonin, niacin, and butyrate, besides to nonsteroidal anti-inflammatory drugs (NSAIDs), and memantine treatment are important aspects of PD therapy. The integration of neuro-immune, antioxidant, and nutritional approaches to treatment should afford better neuroprotection, including by attenuating neuroinflammation, nitro-oxidative stress, mitochondrial dysfunction, and neurodegenerative processes. Future research should clarify the efficacy, and interactions, of nicotine receptor agonists, gut microbiome-derived butyrate, melatonin, and NSAIDs in the treatment of PD.
Read the peer-reviewed publication
Science & TechnologyLife Sciences & BiomedicinePharmacology & PharmacyParkinson's diseaseOxidative stressInflammationNeuroimmunomodulationAntioxidantsNutritionNONSTEROIDAL ANTIINFLAMMATORY DRUGSDIET-INDUCED HYPERKETONEMIAGLUTATHIONE-PEROXIDASEN-ACETYLCYSTEINEMITOCHONDRIAL DYSFUNCTIONLIPID-PEROXIDATIONPASSIVE SMOKINGTRYPTOPHAN CATABOLITESCOGNITIVE DEFICITSParkinson’s disease